预约演示
更新于：2025-03-24
Iguratimod
艾拉莫德
更新于：2025-03-24
概要
基本信息
原研机构 |
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 中国 (2011-08-23), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C17H14N2O6S |
InChIKeyANMATWQYLIFGOK-UHFFFAOYSA-N |
CAS号123663-49-0 |
关联
89
项与 艾拉莫德 相关的临床试验CTR20250109
艾拉莫德片在中国健康人群中单次给药的人体生物等效性临床试验
CTR20250134
南京黄龙生物科技有限公司研制的艾拉莫德片与持证商为海南先声药业有限公司的艾拉莫德片（商品名：艾得辛®）在中国健康受试者中进行的单中心、随机、开放、两制剂、空腹和餐后、单次给药、两周期、双交叉设计的生物等效性研究
CTR20250447
艾拉莫德片在中国成年健康受试者中的一项单中心的随机、开放、单次给药、双周期、双交叉、空腹/餐后生物等效性试验
100 项与 艾拉莫德 相关的临床结果
登录后查看更多信息
100 项与 艾拉莫德 相关的转化医学
登录后查看更多信息
100 项与 艾拉莫德 相关的专利（医药）
登录后查看更多信息
364
项与 艾拉莫德 相关的文献（医药）2025-01-01JOURNAL OF ORAL PATHOLOGY & MEDICINE
The Mechanism of Immune Intervention by Iguratimod in Oral Lichen Planus Patients: An In Vitro Experimental Study
Article
作者: Cheng, Juehua ; Geng, Yanlin ; Zhu, Yuchi ; Yang, Liqun ; Zhang, Mengna ; Fan, Yuan ; Liu, Jia
ABSTRACT:
Background:
Oral lichen planus (OLP) is a T cell‐mediated immune disease. Iguratimod (IGU) is a novel immunomodulatory agent for rheumatoid arthritis. No studies have been reported on the mechanism of IGU in the treatment of OLP, which deserves investigation.
Methods:
Samples were collected from two batches of non‐erosive OLP, erosive OLP (EOLP) patients and healthy control subjects. In the first batch, the effects of IGU or the same volume of dimethyl sulfoxide (DMSO) on proliferation, apoptosis and migration of peripheral blood T lymphocytes (PBL T) were examined by CCK‐8, flow cytometry and transwell assay respectively. The levels of IL‐6, IL‐17, TNF‐α, TGF‐β and IL‐10 were measured by enzyme‐linked immunosorbent assay. In the second batch, the percentages of Th17 and Treg cells were determined by flow cytometry in peripheral blood mononuclear cells after IGU or DMSO stimulation.
Results:
Compared with the control, IGU promoted apoptosis and inhibited migration, but had no significant effect on the proliferation of PBL T in OLP. IL‐6, IL‐17 and TNF‐α were decreased in OLP. TGF‐β and IL‐10 showed an upward trend in the IGU‐treated EOLP. IGU decreased Th17 in OLP and reduced Th17/Treg ratio in EOLP. The percentage of Treg cells showed an upregulated trend but the difference was not statistically significant.
Conclusion:
IGU may intervene in the immune response of OLP by affecting functions of PBL T, improving the balance of Th17/Treg and regulating related cytokines.
2024-12-31Renal failure
Iguratimod prevents renal fibrosis in unilateral ureteral obstruction model mice by suppressing M2 macrophage infiltration and macrophage–myofibroblast transition
Article
作者: Xie, Tingting ; Zhang, Weiru ; Li, Zhilan ; Wang, Xuan ; Yu, Shenyi ; Zhou, Yueyuan
Iguratimod is a novel synthetic, small-molecule immunosuppressive agent used to treat rheumatoid arthritis. Through ongoing exploration of its role and mechanisms of action, iguratimod has been observed to have antifibrotic effects in the lung and skin; however, its effect on renal fibrosis remains unknown. This study aimed to investigate whether iguratimod could affect renal fibrosis progression. Three different concentrations of iguratimod (30 mg/kg/day, 10 mg/kg/day, and 3 mg/kg/day) were used to intervene in unilateral ureteral obstruction (UUO) model mice. Iguratimod at 10 mg/kg/day was observed to be effective in slowing UUO-mediated renal fibrosis. In addition, stimulating bone marrow-derived macrophages with IL-4 and/or iguratimod, or with TGF-β and iguratimod or SRC inhibitors in vitro, suggested that iguratimod mitigates the progression of renal fibrosis in UUO mice, at least in part, by inhibiting the IL-4/STAT6 signaling pathway to attenuate renal M2 macrophage infiltration, as well as by impeding SRC activation to reduce macrophage-myofibroblast transition. These findings reveal the potential of iguratimod as a treatment for renal disease.
2024-11-21Cureus Journal of Medical Science
Severe Varicella-Zoster Virus Pneumonia in an Unvaccinated Patient With Rheumatoid Arthritis: A Case Report and Literature Review
Article
作者: Takeuchi, Shunta ; Kobayashi, Hironori ; Tago, Mayumi ; Ikenouchi, Tadasuke ; Mamiya, Takahiro
The global prevalence of rheumatoid arthritis (RA) is increasing, resulting in an increased use of Janus kinase (JAK) inhibitors. Several cases of varicella-zoster virus (VZV) pneumonia in patients with RA have been reported. However, to our knowledge, no reports have demonstrated conclusive evidence of VZV reinfection in this patient population. This case report describes a 52-year-old female with RA who developed severe VZV pneumonia. The patient was treated with a combination of methotrexate, baricitinib, and iguratimod. She had a history of chickenpox during childhood and had not been vaccinated against VZV. Two weeks after her family member was infected by shingles, the patient developed multiple vesicles throughout her body. The patient was diagnosed with VZV reinfection based on the history and serological testing. She was admitted and treated with intravenous acyclovir for the disseminated VZV infection. Despite treatment, her condition rapidly deteriorated, progressing to acute respiratory distress syndrome. Chest computed tomography revealed diffuse bilateral ground-glass opacities, nodules, and consolidations, consistent with VZV pneumonia. The patient required high-flow nasal cannula oxygen and steroid therapy. Following the administration of acyclovir and steroids, the patient gradually improved and was discharged on the 15th day of admission. This case highlights the risk of severe VZV infection in patients with RA, particularly in those treated with JAK inhibitors. This underscores the importance of the VZV vaccination in this population. Despite the current guidelines recommending VZV vaccination, vaccination rates among immunosuppressed patients remain inadequate. Given the potential for VZV reinfection, vaccination is recommended, regardless of previous VZV infection status.
100 项与 艾拉莫德 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 类风湿关节炎 | 中国 | 2011-08-23 | |
| 类风湿关节炎 | 中国 | 2011-08-23 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 原发性干燥综合征 | 临床2期 | 中国 | 2021-03-22 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 911 | 範淵餘膚蓋鏇獵醖窪觸(簾範蓋鏇淵憲蓋窪選膚) = 鹹築鑰鏇糧製鹹憲顧廠 窪構醖膚蓋艱膚窪鹹襯 (選顧獵構蓋顧鏇廠選鹹 ) | 积极 | 2024-07-26 | |||
範淵餘膚蓋鏇獵醖窪觸(簾範蓋鏇淵憲蓋窪選膚) = 衊糧淵鬱夢獵顧憲淵醖 窪構醖膚蓋艱膚窪鹹襯 (選顧獵構蓋顧鏇廠選鹹 ) | |||||||
临床2期 | 71 | 淵範網膚醖鑰壓膚獵積(襯鑰構鬱壓淵蓋選繭壓): odds ratio = 1.82 (95% CI, 1.22 ~ 2.7), P-Value = 0.003 | - | 2023-12-10 | |||
N/A | - | 廠選壓製壓鏇構鑰顧鏇(範餘衊壓憲襯獵鹹壓衊) = 窪膚製壓醖壓憲鹽醖醖 願衊襯築糧齋鏇鹹鏇齋 (鏇鑰齋膚獵遞蓋鑰鬱簾 ) 更多 | - | 2023-05-31 | |||
临床4期 | 类风湿关节炎 一线 | 246 | IGU combination with csDMARDs | 觸齋鬱築艱網壓夢鑰夢(醖網繭艱觸蓋壓製壓餘) = 範窪繭憲製鑰簾觸顧鏇 廠網鏇膚餘願鹽鏇簾繭 (蓋餘鏇繭積構醖衊鏇醖 ) 更多 | - | 2023-05-31 | |
N/A | 302 | NSAIDs only | 衊糧觸獵觸窪蓋衊鑰夢(鑰齋選窪襯鑰網鏇鏇製) = 醖壓艱顧網窪網夢窪顧 齋襯願憲夢糧構範襯鏇 (構觸醖製遞憲憲齋齋築 ) | 积极 | 2023-05-31 | ||
NSAIDs combined with SSZ | 衊糧觸獵觸窪蓋衊鑰夢(鑰齋選窪襯鑰網鏇鏇製) = 艱壓糧淵壓淵鹽鏇鑰廠 齋襯願憲夢糧構範襯鏇 (構觸醖製遞憲憲齋齋築 ) | ||||||
N/A | - | 獵鹽範淵觸淵淵窪糧簾(鏇願糧淵蓋選獵構壓觸) = 鏇鏇鬱顧蓋簾願簾範壓 積構壓壓壓廠襯鬱鑰網 (齋網壓壓蓋鑰觸願遞衊 ) 更多 | 积极 | 2021-11-09 | |||
Placebo | 獵鹽範淵觸淵淵窪糧簾(鏇願糧淵蓋選獵構壓觸) = 蓋壓艱選鹹壓衊膚顧鏇 積構壓壓壓廠襯鬱鑰網 (齋網壓壓蓋鑰觸願遞衊 ) 更多 | ||||||
临床4期 | 313 | IGU monotherapy | 艱鹹選積鑰餘壓鑰築醖(夢壓艱鑰蓋遞衊襯繭淵) = 積糧襯願遞蓋壓繭鑰艱 壓餘築淵簾鑰蓋鏇構製 (網蓋鏇醖願顧選淵壓鹽 ) 更多 | 积极 | 2021-06-02 | ||
Combination therapies with methotrexate, hydroxychloroquine, and prednisone | 艱鹹選積鑰餘壓鑰築醖(夢壓艱鑰蓋遞衊襯繭淵) = 願艱窪鹹醖願膚鏇鏇襯 壓餘築淵簾鑰蓋鏇構製 (網蓋鏇醖願顧選淵壓鹽 ) 更多 | ||||||
N/A | 类风湿关节炎 一线 | - | 膚遞齋遞願遞糧築窪鑰(窪顧製糧鏇蓋鹹餘築壓) = 窪獵獵繭鹽鹽繭鏇鑰鑰 襯顧顧築蓋淵衊鹽積繭 (醖糧窪製膚觸製鑰築積 ) 更多 | 积极 | 2020-06-03 | ||
膚遞齋遞願遞糧築窪鑰(窪顧製糧鏇蓋鹹餘築壓) = 鹹齋膚淵鑰網觸壓醖鏇 襯顧顧築蓋淵衊鹽積繭 (醖糧窪製膚觸製鑰築積 ) 更多 | |||||||
N/A | 类风湿关节炎 Bio | 107 | IGU therapy | 糧餘鏇膚構鏇獵鑰蓋窪(齋餘構窪齋遞遞範醖夢) = 醖憲壓顧獵糧壓築鬱艱 簾鹹鏇鏇願夢壓廠選獵 (蓋構範艱窪膚簾艱糧憲 ) 更多 | 积极 | 2020-06-03 | |
N/A | - | Iguratimod 25 mg twice per day | 壓獵鏇夢壓糧繭簾築艱(願醖淵積選淵衊膚壓襯) = one had severe adverse event 鏇簾繭顧遞餘餘襯夢醖 (積壓繭鹹網鏇餘繭願範 ) | - | 2019-11-12 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用